Showing 5151-5160 of 5621 results for "".
- Trial of Tele-Ophthalmology System at Regional Health Board in Scotland Shows Promising Resultshttps://modernod.com/news/trial-of-tele-ophthalmology-system-at-regional-health-board-in-scotland-shows-promising-results/2476808/Researchers at the University of Strathclyde and NHS Forth Valley in Scotland have developed a tele-ophthalmology system that, according to recent data, has reduced the need for follow-up appointments and waiting times for treatments in over 50% of cases, according to a
- AcuFocus Completes Study Enrollment for U.S. IDE Clinical Trial of IC-8 Lenshttps://modernod.com/news/acufocus-completes-study-enrollment-for-u-s-ide-clinical-trial-of-ic-8-lens/2476806/AcuFocus announced that it has completed enrollment in its pivotal US investigational device exemption (IDE) study of the company’s IC-8 small aperture IOL. FDA granted approval of the company’s IDE on November 21, 2018, and the Investigational Review Board approved the study just 5
- Oculus Introduces Pentacam AXL Wavehttps://modernod.com/news/oculus-introduces-pentacam-axl-wave/2479548/Oculus has announced that it plans to introduce its next-generation Pentacam—the Pentacam AXL Wave. The new Pentacam AXL Wave is the first device to combine Scheimpflug tomography with axial length, total eye wavefront, objective refraction, and retroillumination, according to Oculus. New
- ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)https://modernod.com/news/proqr-announces-clearance-of-ind-to-start-clinical-trial-of-qr-1123-in-patients-with-autosomal-dominant-retinitis-pigmentosa-adrp/2476802/ProQR Therapeutics announced that the FDA has cleared the investigational new drug (IND) application for QR-1123. ProQR plans to start enrolling patients in a phase 1/2 trial for QR-1123 in 2019. QR-1123 is a first-in-class investigational oligonucleotide designed to address the underlying
- OcuNexus Therapeutics Making Progress with Inflammasome Inhibition Program in Ophthalmic Diseasehttps://modernod.com/news/ocunexus-therapeutics-making-significant-progress-with-inflammasome-inhibition-program-in-ophthalmic-disease/2479550/OcuNexus Therapeutics announced that it has strengthened its board of directors with the addition of Rajiv Shukla, who has deep experience in the investment and commercial aspects of the pharmaceutical industry. OcuNexus Therapeutics is a clinical stage biotechnology company develop
- Bausch Health CEO: Big Pharma Will Survive US Drug Regulationshttps://modernod.com/news/bausch-health-ceo-big-pharma-will-survive-us-drug-regulations/2476798/Bausch Health Chariman and CEO Joseph C. Papa told CNBC on Wednesday that he isn’t too concerned about the future of the pharmaceutical industry despite pledges from Congress to lower
- Optronics Introduces Microcast Pro Medical Grade Microscope Video Camera Platformhttps://modernod.com/news/optronics-introduces-microcast-pro-medical-grade-microscope-video-camera-platform/2476796/Optronics announced the introduction of the next generation Microcast, the Microcast 4K PRO 3CMOS 2160p Ultra High Definition, and Microcast HD PRO 3CMOS 1080p high definition microscope video cameras for surgical and other technical microscope imaging applications including pathology, research,
- Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 in Wet AMDhttps://modernod.com/news/opthea-meets-primary-endpoint-in-phase-2b-study-of-opt-302-in-wet-amd/2476795/Opthea announced positive phase 2b results demonstrating that OPT-302 combination therapy met the primary endpoint of superiority in mean visual acuity gain at 24 weeks compared to Lucentis monotherapy in treatment-naïve patients with wet age-related macular degeneration (AMD). <
- National Center for Children’s Vision and Eye Health at Prevent Blindness Receives Renewed Granthttps://modernod.com/news/national-center-for-childrens-vision-and-eye-health-at-prevent-blindness-receives-renewed-grant/2476794/The National Center for Children’s Vision and Eye Health at Prevent Blindness (NCCVEH), celebrating its 10-year anniversary, has announced that a second year of funding was received from the federal Health Resources and Services Administration’s Maternal and Child Health Bureau for $300,000 to su
- Rare Complication of Eye Surgery Can Kill in a Minutehttps://modernod.com/news/rare-complication-of-eye-surgery-can-kill-in-a-minute/2476790/Ocular venous air embolism, a very rare complication of vitrectomy, is almost always fatal, yet some retina specialists have not heard of it, according to a Medscape report. The complication can kill in less than a minute, said Rob